Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study

References

Page 1

	Year	Citations
Recombinant human acid α-glucosidase Priya S. Kishnani, Deya Corzo, Marc Nicolino, Neurology	2006	759
A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease Ans T. van der Ploeg, Paula R. Clemens, Deyanira Corzo, New England Journal of Medicine	2010	726
A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease Priya S. Kishnani, Wuh‐Liang Hwu, Hanna Mandel, The Journal of Pediatrics PathogenesisNatural HistoryPediatricsInfantile-onset Pompe DiseaseMulticenter Study	2006	578
Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants Priya S. Kishnani, Paula Goldenberg, Stephanie DeArmey, Molecular Genetics and Metabolism VaccinationClinical ImmunologyAutoimmune DiseaseMedicineImmunodeficiencies	2009	372
Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial Andrea Amalfitano, A. Resai Bengur, Richard P. Morse, Genetics in Medicine Translational MedicineBiochemistryInherited Metabolic DiseaseGlycobiologyPediatrics	2001	346
Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling M.G.E.M. Ausems, J. R. Verbiest, MMP Hermans, European Journal of Human Genetics Genetic TestingMendelian DisorderInherited Metabolic DiseaseGenetic EpidemiologyDiabetes	1999	302
Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease Marc Nicolino, Barry J. Byrne, J. Edmund Wraith, Genetics in Medicine Pediatric EpidemiologyClinical EpidemiologyPediatricsAdvanced Pompe DiseaseClinical Outcomes	2009	290
Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe disease Priya S. Kishnani, Marc Nicolino, Thomas Voït, The Journal of Pediatrics Autoimmune DiseasePathogenesisImmunologyGynecologyPathology	2006	282
The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease Suhrad G. Banugaria, Sean N. Prater, Yiu-Ki Ng, Genetics in Medicine Infantile Pompe DiseaseAutoimmune DiseaseAllergyImmunologySerologic Testing	2011	246
Identification of Infants at Risk for Developing Fabry, Pompe, or Mucopolysaccharidosis-I from Newborn Blood Spots by Tandem Mass Spectrometry C. Ronald Scott, Susan Elliott, Norman E. Buroker, The Journal of Pediatrics Developing FabryMedicinePathogenesisBioanalysisPediatrics	2013	159

Page 1